骨科

订阅

MedSci主页 / 所有栏目 / 骨科

Mol Med Rep：含Sr的材料可促进骨缺损的修复

2019-10-01 不详 网络

关注

基于磷酸钙的骨替代品已被广泛用于骨植入手术中的骨修复，增强和重建。尽管其中一些替代品已显示出优异的生物学功效，但仍需要改善当前基于磷酸钙的骨替代品的性能。锶离子（Sr）可以促进成骨作用，抑制破骨细胞形成并增加骨传导性。然而，含锶的α-硫酸钙半水合物（Sr-CaS）的治疗效果和机理尚不清楚。本研究在大鼠中造成了骨骼损伤，并用Sr-CaS治疗了该损伤。然后进行细胞计数试剂盒8，群落形成形成，流式细胞仪

基于磷酸钙的骨替代品已被广泛用于骨植入手术中的骨修复，增强和重建。尽管其中一些替代品已显示出优异的生物学功效，但仍需要改善当前基于磷酸钙的骨替代品的性能。锶离子（Sr）可以促进成骨作用，抑制破骨细胞形成并增加骨传导性。然而，含锶的α-硫酸钙半水合物（Sr-CaS）的治疗效果和机理尚不清楚。

本研究在大鼠中造成了骨骼损伤，并用Sr-CaS治疗了该损伤。然后进行细胞计数试剂盒8，群落形成形成，流式细胞仪，Transwell和茜素红染色测定法，以评估骨细胞的增殖，生长，凋亡，侵袭和成骨分化能力。通过microCT方法，苏木精和曙红染色以及Masson染色来测量骨重建状态。用逆转录定量PCR法分析骨相关因子。通过Western blot分析测定了针对十转化生长因子（TGF）-β，Smad2/3和β-catenin亲缘，并通过免疫组织化学评估了骨钙蛋白（OCN）的表达。

结果显示，Sr-CaS不会显著影响骨髓干细胞（BMSCs）的增殖和凋亡，但会在体外加速BMSCs的迁移和成骨分化。Sr-CaS促进了骨修复，并显著增加了骨矿物质密度，骨体积分数和小梁厚度，但体内的小梁间距以浓度依赖性方式降低。此外，在体外和体内，Sr-CaS均可显著上调与成骨分化相关的基因（Runt相关转录因子2，Osterix，ALP，OCN和骨唾液蛋白）的表达水平。在体外和体内，Sr-CaS还可以提高Smad2/3，TGF-β和磷酸化-β-catenin蛋白的表达。

总之，这些结果表明，含有5％或10％Sr的材料可以通过调节TGF-β/Smad信号通路来改善骨骼缺损。

原始出处：

Liu Z, Yu Z, et al., Strontium containing α calcium sulfate hemihydrate promotes bone repair via the TGF β/Smad signaling pathway. Mol Med Rep. 2019 Oct;20(4):3555-3564. doi: 10.3892/mmr.2019.10592. Epub 2019 Aug 20.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1419331, encodeId=32251419331d5, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Thu Oct 03 12:12:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610012, encodeId=0d3e1610012bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 03 12:12:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373443, encodeId=bc8d3e3443a0, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Oct 02 08:36:51 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373424, encodeId=6a143e3424e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Oct 01 21:25:24 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
    2019-10-03 lfcmxl

    #骨缺损#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1419331, encodeId=32251419331d5, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Thu Oct 03 12:12:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610012, encodeId=0d3e1610012bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 03 12:12:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373443, encodeId=bc8d3e3443a0, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Oct 02 08:36:51 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373424, encodeId=6a143e3424e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Oct 01 21:25:24 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
    2019-10-03 ms3994565386320060

    #Med#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1419331, encodeId=32251419331d5, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Thu Oct 03 12:12:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610012, encodeId=0d3e1610012bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 03 12:12:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373443, encodeId=bc8d3e3443a0, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Oct 02 08:36:51 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373424, encodeId=6a143e3424e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Oct 01 21:25:24 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
    2019-10-02 1ddf0692m34(暂无匿称)

    学习了，谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1419331, encodeId=32251419331d5, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Thu Oct 03 12:12:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610012, encodeId=0d3e1610012bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 03 12:12:00 CST 2019, time=2019-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373443, encodeId=bc8d3e3443a0, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Oct 02 08:36:51 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373424, encodeId=6a143e3424e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Oct 01 21:25:24 CST 2019, time=2019-10-01, status=1, ipAttribution=)]
    2019-10-01 医者仁心5538

    学习了

    0